VWCE (von Willebrand factor C and EGF domains) functions as a tumor suppressor and metabolic regulator with significant clinical implications. The protein acts as a negative regulator of amino acid-dependent mTORC1 signaling by interacting with the KICSTOR complex to facilitate GATOR1 recruitment to lysosomes 1. In cancer contexts, VWCE demonstrates tumor suppressive properties, with downregulated expression observed in breast cancer tissues compared to normal controls 2. VWCE overexpression inhibits proliferation, migration, invasion, and chemoresistance in breast cancer cells, suppressing tumor formation and metastasis through downregulation of WDR1 protein 2. The gene shows hypomethylation in triple-negative breast cancer, contributing to its altered expression patterns 3. Clinically, high VWCE expression correlates with poor prognosis in multiple cancer types, serving as an independent predictor of metastatic recurrence in early-stage colorectal cancer 4 and contributing to prognostic models in oral squamous cell carcinoma 5. VWCE expression is also reduced in prostate cancer, where overexpression inhibits cancer development 1. The protein responds to radiation exposure, making it useful as a biodosimetric marker 6. These findings position VWCE as both a potential therapeutic target and prognostic biomarker across multiple cancer types.